Author

Nathan Beals

New York University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Approach:deep learning· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Craig RamíreziD· 2 shared Abdallah LadayciaiD· 1 shared Akiko Fujimura· 1 shared Akiko KoideiD· 1 shared Alexandra L. McAllaniD· 1 shared Andrew D. HauseriD· 1 shared Andrew Hauser· 1 shared Arwaf S. AlharbiiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Craig RamírezORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Defining the Immunomodulatory Determinants of 3-mer Oligonucleotides on TLR7 and TLR8 sensing

Sunil Sapkota, Zhikuan Zhang, Christine Wolf, Akiko Fujimura, Daniel S. Wenholz, Mary Speir, Lorna E. Wilkinson‐White, ChakYin Chan, Pauline Percier, Abdallah Ladaycia, W. Samantha N. Jayasekara, Arwaf S. Alharbi, Alexandra L. McAllan, Erandi Rupasinghe, Nathan Beals, , Michael Paul Gantier

The paper identifies how 3-mer oligonucleotides with base and sugar modifications modulate TLR7 and TLR8 responses, leading to the development of a dual inhibitory oligonucleotide for autoimmune disease.

bioRxiv · Apr 29, 2026 · PreprintImmunology

Exploiting macropinocytosis for therapeutic intervention in RAS mutant Multiple Myeloma

Nathan Beals, Craig Ramírez, Akiko Koide, Andrew D. Hauser, Faith E. Davies, Shohei Koide, Gareth John Morgan, Dafna Bar‐Sagi

This paper develops a monobody-drug conjugate targeting mutant RAS in multiple myeloma, showing improved anti-tumor effects and safety in vitro and in vivo.

bioRxiv · Apr 4, 2025 · PreprintCancer Biology